It has become evident that various different neuropathologies including Alzheimer's disease neuropathologic change, limbic-predominant age-related TDP-43 encephalopathy neuropathological change (LATE-NC), and argyrophilic grain disease (AGD) coexist in patients with Lewy body disease (LBD). However, the effect of these comorbidities on brain atrophy remains understudied.
Objective
This study aimed to explore the morphological impacts of comorbidities using voxel-based morphometry (VBM).
Methods
Thirty-four individuals with a neuropathological diagnosis of LBD were included. Antemortem whole-brain 3D-T1-weighted images were preprocessed using Computational Anatomy Toolbox 12. Associations between gray matter (GM) atrophy and specific comorbid neuropathology, as well as interactions among them, were analyzed using VBM.
Results
Neurofibrillary tangle (NFT) pathology exhibited inverse correlations with GM volumes of the right temporal, bilateral frontal lobes, and left posterior cingulate gyrus. Neuritic plaque (NP) pathology-related GM atrophy was localized to the left posterior cingulate gyrus and parts of the parietal lobes. LATE-NC exhibited inverse correlations mainly in the left temporal lobe and left-dominant limbic lobes including the hippocampi. AGD pathology-related GM atrophy was predominant in the left-dominant limbic lobes and left temporal pole. Small vessel disease (SVD) scores were inversely correlated with GM volumes in the left frontal lobe and bilateral cerebellar hemispheres. Interactions between NFT and LATE-NC were limited to limbic and temporal lobes, while interactions between NFT and NP, SVD and NFT or LATE-NC showed more posterior-dominant distributions.
Conclusions
VBM analyses revealed distinct atrophy patterns reflective of isolated neuropathologies. Furthermore, the study suggests that interactions between neuropathologies may influence brain atrophy patterns.
LippaCFDudaJEGrossmanM, et al.DLB And PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology2007; 68: 812–819.
2.
McKeithIGBoeveBFDicksonDW, et al.Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium. Neurology2017; 89: 88–100.
3.
McAleeseKECollobySJThomasAJ, et al.Concomitant neurodegenerative pathologies contribute to the transition from mild cognitive impairment to dementia. Alzheimers Dement2021; 17: 1121–1133.
4.
McKeithIGGalaskoDKosakaK, et al.Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology1996; 47: 1113–1124.
5.
Nakashima-YasudaHUryuKRobinsonJ, et al.Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol2007; 114: 221–229.
6.
AdlerCHCavinessJNSabbaghMN, et al.Heterogeneous neuropathological findings in Parkinson's disease with mild cognitive impairment. Acta Neuropathol2010; 120: 827–828.
7.
Colom-CadenaMGrau-RiveraOPlanellasL, et al.Regional overlap of pathologies in Lewy body disorders. J Neuropathol Exp Neurol2017; 76: 216–224.
8.
McKeithIGBallardCGPerryRH, et al.Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology2000; 54: 1050–1058.
9.
SpinaSLa JoieRPetersenC, et al.Comorbid neuropathological diagnoses in early versus late-onset Alzheimer's disease. Brain2021; 144: 2186–2198.
10.
WalkerJMRichardsonTE. Cognitive resistance to and resilience against multiple comorbid neurodegenerative pathologies and the impact of APOE status. J Neuropathol Exp Neurol2023; 82: 110–119.
11.
ChinKSYassiNChurilovL, et al.Prevalence and clinical associations of tau in Lewy body dementias: a systematic review and meta-analysis. Parkinsonism Relat Disord2020; 80: 184–193.
12.
BraakHRübUSteurJ, , et al.Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology2005; 64: 1404–1410.
13.
JellingerKA. Prevalence and impact of cerebrovascular lesions in Alzheimer and Lewy body diseases. Neurodegener Dis2010; 7: 112–115.
14.
NedelskaZFermanTJBoeveBF, et al.Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies. Neurobiol Aging2015; 36: 452–461.
15.
SakuraiKKanedaDMorimotoS, et al.Medial temporal atrophy predicts the limbic comorbidities in Lewy body disease. Neuroradiology2025; 67: 65–77.
16.
FerreiraDNedelskaZGraff-RadfordJ, et al.Cerebrovascular disease, neurodegeneration, and clinical phenotype in dementia with Lewy bodies. Neurobiol Aging2021; 105: 252–261.
17.
InuiSKanedaDSakuraiK, et al.The influence of limbic-predominant age-related TDP-43 encephalopathy on argyrophilic grain disease: a voxel-based morphometry analysis of pathologically confirmed cases. J Neurol Sci2024; 457: 122894.
18.
JosephsKADicksonDWTosakulwongN, et al.Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer's disease: a longitudinal retrospective study. Lancet Neurol2017; 16: 917–924.
19.
PlutaRCzuczwarSJ. Trans- and Cis-phosphorylated tau protein: new pieces of the puzzle in the development of neurofibrillary tangles in post-ischemic brain neurodegeneration of the Alzheimer's disease-like type. Int J Mol Sci2024; 25: 3091.
20.
ThammisettySSRenaudLPicher-MartelV, et al.Targeting TDP-43 pathology alleviates cognitive and motor deficits caused by chronic cerebral hypoperfusion. Neurotherapeutics2021; 18: 1095–1111.
21.
DicksonDWBraakHDudaJE, et al.Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol2009; 8: 1150–1157.
22.
LitvanIHauwJJBartkoJJ, et al.Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol1996; 55: 97–105.
23.
RobinsonJLPortaSGarrettFG, et al.Limbic-predominant age-related TDP-43 encephalopathy differs from frontotemporal lobar degeneration. Brain2020; 143: 2844–2857.
24.
EmreMAarslandDBrownR, et al.Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord2007; 22: 1689–1707.
25.
SakuraiKKanedaDMorimotoS, et al.Asymmetric cerebral peduncle atrophy: a simple diagnostic clue for distinguishing frontotemporal lobar degeneration from Alzheimer's disease. J Alzheimers Dis2023; 95: 1657–1665.
MirraSSHeymanAMcKeelD, et al.The consortium to establish a registry for Alzheimer's disease (CERAD). part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology1991; 41: 479–486.
28.
NelsonPTLeeEBCykowskiMD, et al.LATE-NC staging in routine neuropathologic diagnosis: an update. Acta Neuropathol2023; 145: 159–173.
29.
Amin Al OlamaAWasonJMSTuladharAM, et al.Simple MRI score aids prediction of dementia in cerebral small vessel disease. Neurology2020; 94: e1294–e1302.
30.
WeiMJoshiAAZhangM, et al.How age of acquisition influences brain architecture in bilinguals. J Neurolinguistics2015; 36: 35–50.
31.
WadstenC. Sensitivity of the EQ-5D-5L for fatigue, memory and concentration problems, and dyspnea, and their added value in patients after COVID-19 with persistent long-term symptoms: an application of multiple linear regression and LASSO. Dissertation, Uppsala University, Uppsala, Sweden, 2023. Retrieved from https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-504216
32.
PiniLPievaniMBocchettaM, et al.Brain atrophy in Alzheimer's disease and aging. Ageing Res Rev2016; 30: 25–48.
33.
ScahillRISchottJMStevensJM, et al.Mapping the evolution of regional atrophy in Alzheimer's disease: unbiased analysis of fluid-registered serial MRI. Proc Natl Acad Sci U S A2002; 99: 4703–4707.
34.
BraakHBraakE. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol1991; 82: 239–259.
35.
OssenkoppeleRLyooCHSudreCH, et al.Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer's disease. Alzheimers Dement2020; 16: 335–344.
36.
BurtonEJBarberRMukaetova-LadinskaEB, et al.Medial temporal lobe atrophy on MRI differentiates Alzheimer's disease from dementia with Lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosis. Brain2009; 132: 195–203.
37.
JosephsKAMurrayMEWhitwellJL, et al.Updated TDP-43 in Alzheimer's disease staging scheme. Acta Neuropathol2016; 131: 571–585.
38.
KotrotsouASchneiderJABennettDA, et al.Neuropathologic correlates of regional brain volumes in a community cohort of older adults. Neurobiol Aging2015; 36: 2798–2805.
39.
NagSYuLBoylePA, et al.TDP-43 pathology in anterior temporal pole cortex in aging and Alzheimer's disease. Acta Neuropathol Commun2018; 6: 33.
40.
MakkinejadNSchneiderJAYuJ, et al.Associations of amygdala volume and shape with transactive response DNA-binding protein 43 (TDP-43) pathology in a community cohort of older adults. Neurobiol Aging2019; 77: 104–111.
41.
SakuraiKKanedaDMorimotoS, et al.Diverse limbic comorbidities cause limbic and temporal atrophy in Lewy body disease. Parkinsonism Relat Disord2022; 105: 52–57.
42.
SakuraiKKanedaDMorimotoS, et al.Voxel-based and surface-based morphometry analysis in patients with pathologically confirmed argyrophilic grain disease and Alzheimer's disease. J Alzheimers Dis2023; 93: 379–387.
43.
SakuraiKTokumaruAMIkedaT, et al.Characteristic asymmetric limbic and anterior temporal atrophy in demented patients with pathologically confirmed argyrophilic grain disease. Neuroradiology2019; 61: 1239–1249.
44.
AdachiTSaitoYHatsutaH, et al.Neuropathological asymmetry in argyrophilic grain disease. J Neuropathol Exp Neurol2010; 69: 737–744.
45.
JosephsKAWhitwellJLParisiJE, et al.Argyrophilic grains: a distinct disease or an additive pathology?Neurobiol Aging2008; 29: 566–573.
46.
JungWBMunCWKimYH, et al.Cortical atrophy, reduced integrity of white matter and cognitive impairment in subcortical vascular dementia of Binswanger type. Psychiatry Clin Neurosci2014; 68: 821–832.
47.
LambertCSam NareanJBenjaminP, et al.Characterising the grey matter correlates of leukoaraiosis in cerebral small vessel disease. Neuroimage Clin2015; 9: 194–205.
48.
VangbergTREikenesLHåbergAK. The effect of white matter hyperintensities on regional brain volumes and white matter microstructure, a population-based study in HUNT. Neuroimage2019; 203: 116158.
49.
Apátiga-PérezRSoto-RojasLOCampa-CórdobaBB, et al.Neurovascular dysfunction and vascular amyloid accumulation as early events in Alzheimer's disease. Metab Brain Dis2022; 37: 39–50.
50.
AgrawalSYuLKapasiA, et al.Limbic-predominant age-related TDP-43 encephalopathy neuropathologic change and microvascular pathologies in community-dwelling older persons. Brain Pathol2021; 31: e12939.
51.
ToméSOGaworKThalDR. LATE-NC in Alzheimer's disease: molecular aspects and synergies. Brain Pathol2024; 34: e13213.
52.
BlancFCollobySJPhilippiN, et al.Cortical thickness in dementia with Lewy bodies and Alzheimer's disease: a comparison of prodromal and dementia stages. PLoS One2015; 10: e0127396.
53.
CollobySJO'BrienJTTaylorJP. Patterns of cerebellar volume loss in dementia with Lewy bodies and Alzheimer's disease: a VBM-DARTEL study. Psychiatry Res2014; 223: 187–191.
54.
GalliAPilottoAChiariniB, et al.Occipital atrophy signature in prodromal Lewy bodies disease. Alzheimers Dement2023; 15: e12462.
55.
JamerlanAMSSAA. A microplate-based approach to map interactions between TDP-43 and α-synuclein. J Clin Med2022; 11: 573.
56.
DhakalSWyantCEGeorgeHE, et al.Prion-like C-terminal domain of TDP-43 and α-synuclein interact synergistically to generate neurotoxic hybrid fibrils. J Mol Biol2021; 433: 166953.
57.
KokoulinaPRohnTT. Caspase-cleaved transactivation response DNA-binding protein 43 in Parkinson's disease and dementia with Lewy bodies. Neurodegener Dis2010; 7: 243–250.
58.
WhitwellJLJosephsKAMurrayME, et al.MRI Correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology2008; 71: 743–749.
59.
BejaninAMurrayMEMartinP, et al.Antemortem volume loss mirrors TDP-43 staging in older adults with non-frontotemporal lobar degeneration. Brain2019; 142: 3621–3635.
60.
Quintas-NevesMTeylanMABesserL, et al.Magnetic resonance imaging brain atrophy assessment in primary age-related tauopathy (PART). Acta Neuropathol Commun2019; 7: 204.
61.
WoodworthDCSheikh-BahaeiNScambrayKA, et al.Dementia is associated with medial temporal atrophy even after accounting for neuropathologies. Brain Commun2022; 4: fcac052.
